MARKET

BLCM

BLCM

Bellicum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.180
-0.020
-0.63%
Closed 16:00 04/19 EDT
OPEN
3.180
PREV CLOSE
3.200
HIGH
3.250
LOW
2.930
VOLUME
276.76K
TURNOVER
--
52 WEEK HIGH
9.56
52 WEEK LOW
2.620
MARKET CAP
26.45M
P/E (TTM)
-1.1108
1D
5D
1M
3M
1Y
5Y
Dendritic Cell Cancer Vaccine Market 2021 Analysis by Key Players, End-User, Type, Application, Regions and Forecast to 2027
Apr 19, 2021 (Market Insight Reports) -- The latest report as Dendritic Cell Cancer Vaccine Market acknowledges Size, Application Segment, Type, Regional...
Market Insight Reports · 21h ago
Bellicum Pharmaceuticals Stock Shows Every Sign Of Being Significantly Overvalued
GuruFocus News · 3d ago
Global Rhabdomyosarcoma Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Rhabdomyosarcoma Drug market report provides a detailed analysis of global market size, regional and country-level market...
Heraldkeepers · 4d ago
Bone Marrow Transplant Rejection Treatment Market Research 2027 Distribution Status by Players, Market Size Analysis and Forecast by Type and Application
The Express Wire · 4d ago
Bone Marrow Transplant Rejection Treatment Market Professional Survey, Growth, Shares, Opportunities and Forecast to 2027
Market Stats News · 04/08 18:32
Rhabdomyosarcoma Drug Market Size, Industry Share 2021 ,Market Research with Growth, Manufacturers, Segments and 2027 Forecasts Research
Apr 06, 2021 (Market Insight Reports) -- CANADA - QYResearchMedical recently added a research report, Rhabdomyosarcoma Drug market – global industry size,...
Market Insight Reports · 04/06 19:04
Amniotic Membranes Market Research Report by Security Type, by Service Type, by Industry – Global Forecast to 2025 – Cumulative Impact of COVID-19
Apr 06, 2021 (Heraldkeepers) -- The Amniotic Membranes Market is expected to exceed more than US$ 1.63 Billion by 2024 at a CAGR of 9.7% in the given...
Heraldkeepers · 04/06 14:36
Bursitis Treatment Market Overview, New Opportunities & SWOT Analysis by 2025 | Pfizer, Amgen, Bayer, MediaPharma
Market Insight Reports · 04/06 14:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLCM. Analyze the recent business situations of Bellicum Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLCM stock price target is 4.500 with a high estimate of 4.500 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 101
Institutional Holdings: 9.47M
% Owned: 113.84%
Shares Outstanding: 8.32M
TypeInstitutionsShares
Increased
3
2.07K
New
16
964.07K
Decreased
7
190.12K
Sold Out
5
189.82K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.60%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Independent Director
James Brown
President/Chief Executive Officer/Director
Richard Fair
Senior Vice President
Aaron Foster
Independent Director
James Daly
Independent Director
Stephen Davis
Independent Director
Reid Huber
Independent Director
Judith Klimovsky
Independent Director
Jon Stonehouse
No Data
About BLCM
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.

Webull offers kinds of Bellicum Pharmaceuticals Inc stock information, including NASDAQ:BLCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLCM stock methods without spending real money on the virtual paper trading platform.